Safety and Efficacy of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open-label extension period of the Phase 2 STRIDE study

By afschroeder • October 9, 2025

Papp KA, Jacobs S, Sofen H, Bukhalo M, Muscianisi E, Ma G, Lau G, Bettinger M, Rubio RG, Hitraya E, Blauvelt A; Open-Label Extension study team. Safety and Efficacy of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open-label extension period of the Phase 2 STRIDE study. J Am Acad Dermatol. 2025 Oct 6:S0190-9622(25)02952-4. doi: 10.1016/j.jaad.2025.10.005. Epub ahead of print. PMID: 41061968.

Tags: Dermatology, durability, efficacy, envudeucitinib, ESK-001, long-term extension, Olive View DoM, phase 2, plaque psoriasis, Publications, safety, STRIDE, TYK2

Differentially Expressed Salivary miRNAs in Temporomandibular Disorders

Kaczor-Urbanowicz KE, Aziz M, Wilhalme H, Aronovich S, Hatfield ER, Aghaloo T, Arman S, Mohammadi A, Husain M, Tetradis S, Elashoff D, Pellegrini M, Wong[...]

Neurotrophic Tyrosine Receptor Kinase-Rearranged Spindle Cell Neoplasm Presenting on the Breast of a 44-Year-Old Woman

Saka F, McKenzie S, Milani-Nejad N, Smart C. Neurotrophic Tyrosine Receptor Kinase-Rearranged Spindle Cell Neoplasm Presenting on the Breast of a 44-Year-Old Woman. Am J[...]

Probing DNA damage in Rett syndrome neurons uncovers a role for MECP2 regulation of PARP1

Morales A, Korsakova E, Mansooralavi N, Ravikumar A, Rivas G, Soliman P, Rodriguez L, McDaniel T, Lund A, Cooper B, Bhaduri A, Lowry WE. Probing[...]